European Medicines Agency (EMA) has accepted Pfizer's regulatory
submissions for review of two investigational compounds crizotinib, an
oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
Crizotinib
Bosutinib
Dr. Andreas Penk, president of Pfizer Oncology Europe, claims that,
"With the EMA submissions for crizotinib and bosutinib, we are one step closer to potentially bringing two promising agents to patient populations in areas of significant unmet medical need"......
